Cargando…

Immunogenic Cell Death in Hematological Malignancy Therapy

Although the curative effect of hematological malignancies has been improved in recent years, relapse or drug resistance of hematological malignancies will eventually recur. Furthermore, the microenvironment disorder is an important mechanism in the pathogenesis of hematological malignancies. Immuno...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhaoyun, Xu, Xintong, Liu, Kaining, Zhang, Jingtian, Ding, Dan, Fu, Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10161053/
https://www.ncbi.nlm.nih.gov/pubmed/36815385
http://dx.doi.org/10.1002/advs.202207475
_version_ 1785037410042642432
author Liu, Zhaoyun
Xu, Xintong
Liu, Kaining
Zhang, Jingtian
Ding, Dan
Fu, Rong
author_facet Liu, Zhaoyun
Xu, Xintong
Liu, Kaining
Zhang, Jingtian
Ding, Dan
Fu, Rong
author_sort Liu, Zhaoyun
collection PubMed
description Although the curative effect of hematological malignancies has been improved in recent years, relapse or drug resistance of hematological malignancies will eventually recur. Furthermore, the microenvironment disorder is an important mechanism in the pathogenesis of hematological malignancies. Immunogenic cell death (ICD) is a unique mechanism of regulated cell death (RCD) that triggers an intact antigen‐specific adaptive immune response by firing a set of danger signals or damage‐associated molecular patterns (DAMPs), which is an immunotherapeutic modality with the potential for the treatment of hematological malignancies. This review summarizes the existing knowledge about the induction of ICD in hematological malignancies and the current research on combining ICD inducers with other treatment strategies for hematological malignancies.
format Online
Article
Text
id pubmed-10161053
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-101610532023-05-06 Immunogenic Cell Death in Hematological Malignancy Therapy Liu, Zhaoyun Xu, Xintong Liu, Kaining Zhang, Jingtian Ding, Dan Fu, Rong Adv Sci (Weinh) Reviews Although the curative effect of hematological malignancies has been improved in recent years, relapse or drug resistance of hematological malignancies will eventually recur. Furthermore, the microenvironment disorder is an important mechanism in the pathogenesis of hematological malignancies. Immunogenic cell death (ICD) is a unique mechanism of regulated cell death (RCD) that triggers an intact antigen‐specific adaptive immune response by firing a set of danger signals or damage‐associated molecular patterns (DAMPs), which is an immunotherapeutic modality with the potential for the treatment of hematological malignancies. This review summarizes the existing knowledge about the induction of ICD in hematological malignancies and the current research on combining ICD inducers with other treatment strategies for hematological malignancies. John Wiley and Sons Inc. 2023-02-23 /pmc/articles/PMC10161053/ /pubmed/36815385 http://dx.doi.org/10.1002/advs.202207475 Text en © 2023 The Authors. Advanced Science published by Wiley‐VCH GmbH https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
Liu, Zhaoyun
Xu, Xintong
Liu, Kaining
Zhang, Jingtian
Ding, Dan
Fu, Rong
Immunogenic Cell Death in Hematological Malignancy Therapy
title Immunogenic Cell Death in Hematological Malignancy Therapy
title_full Immunogenic Cell Death in Hematological Malignancy Therapy
title_fullStr Immunogenic Cell Death in Hematological Malignancy Therapy
title_full_unstemmed Immunogenic Cell Death in Hematological Malignancy Therapy
title_short Immunogenic Cell Death in Hematological Malignancy Therapy
title_sort immunogenic cell death in hematological malignancy therapy
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10161053/
https://www.ncbi.nlm.nih.gov/pubmed/36815385
http://dx.doi.org/10.1002/advs.202207475
work_keys_str_mv AT liuzhaoyun immunogeniccelldeathinhematologicalmalignancytherapy
AT xuxintong immunogeniccelldeathinhematologicalmalignancytherapy
AT liukaining immunogeniccelldeathinhematologicalmalignancytherapy
AT zhangjingtian immunogeniccelldeathinhematologicalmalignancytherapy
AT dingdan immunogeniccelldeathinhematologicalmalignancytherapy
AT furong immunogeniccelldeathinhematologicalmalignancytherapy